IL315632A - Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment - Google Patents

Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment

Info

Publication number
IL315632A
IL315632A IL315632A IL31563224A IL315632A IL 315632 A IL315632 A IL 315632A IL 315632 A IL315632 A IL 315632A IL 31563224 A IL31563224 A IL 31563224A IL 315632 A IL315632 A IL 315632A
Authority
IL
Israel
Prior art keywords
adm
antibody
adrenomedullin
formulation
patient
Prior art date
Application number
IL315632A
Other languages
English (en)
Hebrew (he)
Inventor
Jarrid Goldstein
Original Assignee
Adrenomed Ag
Jarrid Goldstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed Ag, Jarrid Goldstein filed Critical Adrenomed Ag
Publication of IL315632A publication Critical patent/IL315632A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL315632A 2022-03-15 2023-03-15 Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment IL315632A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22162271 2022-03-15
PCT/EP2023/056663 WO2023175035A1 (en) 2022-03-15 2023-03-15 Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment

Publications (1)

Publication Number Publication Date
IL315632A true IL315632A (en) 2024-11-01

Family

ID=80780591

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315632A IL315632A (en) 2022-03-15 2023-03-15 Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment

Country Status (9)

Country Link
US (1) US20250304671A1 (https=)
EP (1) EP4493588A1 (https=)
JP (1) JP2025509304A (https=)
CN (1) CN119072492A (https=)
AU (1) AU2023233838A1 (https=)
CA (1) CA3254142A1 (https=)
IL (1) IL315632A (https=)
MX (1) MX2024010899A (https=)
WO (1) WO2023175035A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025056807A1 (en) * 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2025133235A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Adm-gly as marker for early predicting sepsis
WO2026046978A1 (en) * 2024-08-26 2026-03-05 Pam Theragnostics Gmbh Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
EP1620734A1 (en) 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PL2594588T3 (pl) 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP4086283A1 (en) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
AU2017252212B2 (en) 2016-04-21 2023-09-07 4TEEN4 Pharmaceuticals GmbH Methods for determining DPP3 and therapeutic methods
KR20240033285A (ko) 2016-12-16 2024-03-12 아드레노메드 아게 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
SG11202002268XA (en) * 2017-10-18 2020-04-29 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
CA3168978A1 (en) * 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock

Also Published As

Publication number Publication date
AU2023233838A1 (en) 2024-09-26
WO2023175035A1 (en) 2023-09-21
CA3254142A1 (en) 2023-09-21
CN119072492A (zh) 2024-12-03
EP4493588A1 (en) 2025-01-22
US20250304671A1 (en) 2025-10-02
JP2025509304A (ja) 2025-04-11
MX2024010899A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20250304671A1 (en) Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
Laterre et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
US20230257456A1 (en) High concentration anti-c5 antibody formulations
JP6193871B2 (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
KR20220019656A (ko) 경쇄 아밀로이드증 치료 방법
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
JP2024086898A (ja) テルリプレシン組成物及びその使用
KR102403388B1 (ko) 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도
WO2022017468A1 (zh) Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途
US20260070996A1 (en) Formulations for anti-insulin receptor antibody and uses thereof
JP2016534062A (ja) 新規な安定製剤
US20220040301A1 (en) Anti-IL-6 Antibody Formulation
WO2021052472A1 (zh) 抗pcsk9抗体用于预防或治疗胆固醇相关疾病的方法
KR20240133743A (ko) Al 아밀로이드증 치료 방법
JP2024505923A (ja) Ａｌアミロイドーシスを処置する方法
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
US20260022197A1 (en) Methods of reversing ticagrelor activity
EP4345109A1 (en) Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease
HK40058594A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
KR20260057482A (ko) 항인슐린 수용체 항체에 대한 고농도 제형 및 그의 용도
Li et al. Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction
WO2025056655A1 (en) Antibody formulation
KR20230121797A (ko) 항-il5r 항체 제형
IL295951A (en) Antiadrenomedullin (adm) binders for use in the treatment of shock patients